EuroBiotech: More Articles of Note


> Prexton Therapeutics began a phase 2 trial of its Parkinson’s disease candidate. The Merck Serono spinout is testing two doses of foliglurax against placebo in 165 patients who are experiencing the wearing-off of levodopa and levodopa-induced dyskinesia. Data are due in 2019. Statement

> Cellectis unveiled plans for a $100 million IPO of its gene editing agriculture company. The off-the-shelf CAR-T player will retain the largest stake in Calyxt. Release

> Pfenex received a milestone payment from Johnson & Johnson. The milestone was triggered by the advance of a RORgt inhibitor into phase 1. Pfenex and J&J discovered the candidate as part of a deal they struck in 2012. Statement


Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

> Horama picked up an orphan drug designation for its retinitis pigmentosa gene therapy. The FDA nod marks another small step forward for the French biotech helmed by Christine Placet, the biotech executive who led Trophos to a €470 million takeover by Roche. Release  

> BioInvent and ThromboGenics tweaked their monoclonal antibody agreement. The revised terms put BioInvent in charge of developing TB-403 in cancer indications and dials up its stake in the asset. ThromboGenics has taken full ownership of THR-317. Statement

> A phase 2b trial of Neovacs’ lupus candidate came through an interim data review. The trial is now fully enrolled and has clearance to push ahead, setting up Neovacs to deliver data in the second quarter of 2018. Release

Suggested Articles

Pfizer licensed the drugs, gamma secretase inhibitor nirogacestat and MEK inhibitor mirdametinib, to SpringWorks in 2017.

The company, which was co-founded by Jim Mellon, has reeled in $165 million in 18 months to establish itself at the forefront of the longevity field.

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy.